Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis.

By Farrell Rachel   Bendtzen Klaus   Bertolotto Antonio   Clark Berwyn   Comabella Manuel   Deisenhammer Florian   Fogdell-Hahn Anna   Giovannoni Gavin   Hartung Hans Peter   Hemmer Bernard   Hillert Jan   Kappos Ludwig   Killestein Joep   Lindberg Raija   Montalban Xavier   Polman Chris   Sorensen Per Soelberg   Goodin DS   Hurwitz B   Noronha A  

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 204-210

Field House Publishing

Access to resources Recommend Favorite

Interferon-β_1b for the treatment of multiple sclerosis

By Lam Sum   Wang Shan   Gottesman Malcolm  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 8, 2008-08 ,pp. : 1111-1117

Informa Healthcare

Access to resources Recommend Favorite

Interferon-β_1b in the treatment of multiple sclerosis

By Río Jordi   Montalban Xavier  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2877-2886

Informa Healthcare

Access to resources Recommend Favorite

Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis: Prevalence and Impact on Outcomes

By Deisenhammer Florian  

CNS Drugs, Vol. 23, Iss. 5, 2009-05 ,pp. : 379-396

Adis International

Access to resources Recommend Favorite

Interferon-β-1b: A Review of its Use in Multiple Sclerosis

By Plosker Greg L.  

CNS Drugs, Vol. 25, Iss. 1, 2011-01 ,pp. : 67-88

Adis International

Access to resources Recommend Favorite